| Literature DB >> 32907879 |
Shota Ozawa1,2, Masaya Matsubayashi3, Hitoki Nanaura3, Motoko Yanagita1,4,5, Kiyoshi Mori1,6, Katsuhiko Asanuma1,7, Nobuyuki Kajiwara8, Kazuyuki Hayashi8, Hiroshi Ohashi9, Masato Kasahara10, Hideki Yokoi4, Hiroaki Kataoka11, Eiichiro Mori12, Takahiko Nakagawa13,3.
Abstract
Podocyte injury is a critical step toward the progression of renal disease and is often associated with a loss of slit diaphragm proteins, including Podocin. Although there is a possibility that the extracellular domain of these slit diaphragm proteins can be a target for a pathological proteolysis, the precise mechanism driving the phenomenon remains unknown. Here we show that Matriptase, a membrane-anchored protein, was activated at podocytes in CKD patients and mice, whereas Matriptase inhibitors slowed the progression of mouse kidney disease. The mechanism could be accounted for by an imbalance favoring Matriptase over its cognate inhibitor, hepatocyte growth factor activator inhibitor type 1 (HAI-1), because conditional depletion of HAI-1 in podocytes accelerated podocyte injury in mouse model. Matriptase was capable of cleaving Podocin, but such a reaction was blocked by either HAI-1 or dominant-negative Matriptase. Furthermore, the N terminus of Podocin, as a consequence of Matriptase cleavage of Podocin, translocated to nucleoli, suggesting that the N terminus of Podocin might be involved in the process of podocyte injury. Given these observations, we propose that the proteolytic cleavage of Podocin by Matriptase could potentially cause podocyte injury and that targeting Matriptase could be a novel therapeutic strategy for CKD patients.Entities:
Keywords: Matriptase; Podocin; chronic kidney disease; diabetic nephropathy; hepatocyte growth factor activator inhibitor type 1; kidney; podocyte; protease; protease inhibitor
Year: 2020 PMID: 32907879 PMCID: PMC7681011 DOI: 10.1074/jbc.RA120.013721
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157